Pfizer to divide firm into three businesses
Pfizer has unveiled plans to restructure the company into three business units, separating biosimilars, generics and OTC medicines. Biosimilars will be housed in the US firm’s ‘Innovative Medicines’ division, alongside a new hospital business unit for anti-infectives and sterile injectables; an ‘Established Medicines’ segment will incorporate “certain generics” with Pfizer’s off-patent solid oral-dose legacy brands, “operating with substantial autonomy within Pfizer”; and a ‘Consumer Healthcare’ division will include the company’s OTC medicines. The changes will come into effect at the start of 2019.
You may also be interested in...
Following the announcement of a merger between Mylan and Pfizer’s Upjohn, the top executive team that will take charge of the combination has set out its vision for the company.
Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.
Pfizer’s long-standing sterile injectable supply and manufacturing issues pummelled respective sales in the US in 2018. But the US-based multinational is eyeing a string of oncology biosimilar launches in 2019, which could see biosimilar sales tick past US$1 billion.